DailyIQ
|
Sector:HealthcareAll sectors
Last updated 8 minutes ago

CRSP·CRISPR Therapeutics AG

$.
-. (-.%)
After Hours
High
$56.77
Open
$56.33
Market Cap
5.15B
52W High
$78.48
Low
$52.05
P. Close
$53.37
P/E
-
52W Low
$44.12
Fwd P/E
-13.79
DailyIQ Est.
$100.34
Technical Score (1D)
50
NEUTRAL
News Sentiment
54
MIXED
CRISPR Therapeutics shares fell 5.3% today after the market, driven by analysts’ projection of a $1.12 per share loss despite a 733 % revenue jump to $7.42 million. The sharp decline reflects investors’ concern that the top‑line growth may not translate into profitability in the near term. The company’s earnings release, due in the next few days, will be closely watched for guidance on margin improvement and the status of its pipeline. If guidance confirms that the loss will widen or that product launches are delayed, the stock could see further downside. Conversely, any sign of improved gross margins or a new product milestone could quickly reverse the negative sentiment. The broader context is that CRISPR’s gene‑editing platform has broad therapeutic potential but has yet to secure many FDA approvals, creating short‑term risk. The company’s valuation remains high relative to its current revenue, so any pipeline milestone or approval announcement could serve as a catalyst for a valuation reset. Traders should watch the earnings call for updates on the clinical progress of its lead candidates and any new regulatory interactions. Additionally, keep an eye on the timing of the next FDA review cycle, as a favorable decision could shift the outlook for the next 1–10 trading days.
Earnings Summary
CRISPR Therapeutics AG, a German gene‑editing company founded in 2016, develops CRISPR/Cas9‑based therapies for hemoglobinopathies, oncology, and other serious diseases, positioning it within the biotechnology healthcare sector. In its most recent fiscal quarter, the company reported earnings per share of –$0.44 against an estimate of –$1.19 and generated $35.7 million in revenue, a beat that reflects early commercial activity from its first product launch; the company’s revenue has grown modestly from $0.9 million in Q1 2025 to $0.89 million in Q3 2025, indicating a plateau in sales volume. Historically, CRISPR has shown a pattern of negative earnings but improving margins, with the latest quarter exceeding analyst expectations and the company’s revenue trajectory suggesting incremental growth, although detailed YoY data are limited in the provided set. The company’s Q4 2024 EPS beat and Q2 2025 EPS beat demonstrate a trend of earnings improvement, while the Q1 2025 miss highlights the volatility inherent in early‑stage biotech commercialization. Recent news highlights the launch of Casgevy for sickle cell disease and beta‑thalassemia, the first commercial milestone that could drive future revenue; analysts have upgraded the stock to a Market‑Outperform rating and maintained an $80 price target, signaling confidence in the pipeline. Forward‑looking watch points for investors include the forthcoming Q4 2025 earnings release, where management will discuss revenue guidance, pipeline milestones, and any updates on the Vertex partnership; attention to clinical data, regulatory approvals, and diversification of the customer base will be key to assessing whether the company can sustain its growth trajectory.

EPS

EstBeatMiss
$-1.75$-1.38$-1.01$-0.64$-0.27Q4'24Q1'25Q2'25Q3'25Q4'25
QtrEstActual+/−
Q4'25$-1.19 - -
Q3'25$-1.29$-1.17+9.2%
Q2'25$-1.40$-1.29+7.8%
Q1'25$-1.28$-1.58-23.8%
Q4'24$-1.19$-0.44+62.9%

Revenue

EstBeatMiss
$-4M$7M$18M$30M$41MQ4'24Q1'25Q2'25Q3'25Q4'25
QtrEstActual+/−
Q4'25$7M - -
Q3'25 - $889,000 -
Q2'25 - $892,000 -
Q1'25 - $865,000 -
Q4'24 - $36M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CRSP Stock Snapshot

CRSP is currently trading at $53.39, giving CRISPR Therapeutics AG a market cap of 5.15B. Today's range spans $52.05–$56.77, with shares opening at $56.33 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 54/100.

Over the past year CRSP has traded between $44.12 and $78.48 - the current price is +21.0% off the 52-week low and -32.0% from the high. 34 analysts cover the stock with a Hold consensus and a mean 12-month target of $84.70 (range $44.00–$291.00), implying upside of +58.6%.

The bid/ask spread on CRSP widens when the technical picture is non-constructive - at 5.15B in Healthcare market cap, HOLD signals (50/100) with neutral sentiment (54/100) reduce market maker willingness to provide tight liquidity. Price: $53.39 (in the lower half of its 52-week range in $44.12–$78.48). This isn't just a trading cost - wider spreads signal reduced conviction from participants closest to the order flow, which is often an early warning that the mixed setup has more room to run than the score alone suggests.

Small-cap Healthcare names with HOLD technicals (50/100) and neutral sentiment (54/100) like CRSP tend to experience sentiment-driven re-ratings more sharply in both directions. At $53.39 (in the lower half of its 52-week range in $44.12–$78.48), the current setup suggests a stock that needs a material positive catalyst — not incremental improvement — to reverse the technical and sentiment readings that now define the 5.15B market cap trajectory.